These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32026357)

  • 1. Correlation between haemoglobin level and type of erythropoiesis-stimulating agent at initiation of haemodialysis.
    Higashiura M; Ohya M; Tanaka Y; Yano T; Yamamoto S; Mima T; Negi S; Shigematsu T
    Int J Clin Pharm; 2020 Apr; 42(2):635-641. PubMed ID: 32026357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents.
    Io H; Aizawa M; Funabiki K; Horikoshi S; Tomino Y
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():7-13. PubMed ID: 26439537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].
    Anaya S; Rivera F; Sánchez de la Nieta MD; Carreño A; Vozmediano C; Alcaide MP; Arambarri M; Nieto J; Caparrós G; Ferreras I
    Nefrologia; 2008; 28(2):186-92. PubMed ID: 18454709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease.
    Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S
    Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
    Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
    Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13.
    Birnie K; Caskey F; Ben-Shlomo Y; Sterne JA; Gilg J; Nitsch D; Tomson C
    Nephrol Dial Transplant; 2017 Apr; 32(4):692-698. PubMed ID: 27190350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
    Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
    Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of erythropoiesis-stimulating agents in patients undergoing haemodialysis: A time and motion study.
    Johnson DW; Cleland B; Eris J; Rafferty T; Sud K; Chow JS
    J Ren Care; 2017 Dec; 43(4):219-225. PubMed ID: 28901048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
    Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
    BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres.
    Roche A; Macdougall IC; Walker RG
    Curr Med Res Opin; 2009 Dec; 25(12):2971-6. PubMed ID: 19842997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled open-label trial of vitamin E-bonded polysulfone dialyzer and erythropoiesis-stimulating agent response.
    Sanaka T; Mochizuki T; Kinugasa E; Kusano E; Ohwada S; Kuno T; Kojima K; Kobayashi S; Satoh M; Shimada N; Nakao K; Nakazawa R; Nishimura H; Noiri E; Shigematsu T; Tomo T; Maeda T;
    Clin J Am Soc Nephrol; 2013 Jun; 8(6):969-78. PubMed ID: 23599410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between anaemia management at haemodialysis initiation and patient prognosis.
    Kataoka H; Tsuchiya K; Naganuma T; Okazaki M; Komatsu M; Kimura T; Shiohira S; Kawaguchi H; Nitta K
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():14-21. PubMed ID: 26456159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis.
    Hazara AM; Owen SJ; Bhandari S
    Blood Purif; 2016; 41(4):287-92. PubMed ID: 26820617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience.
    Jesus-Silva JA; Lamplugh A; Dhada S; Burton JO; Bhandari S
    BMC Nephrol; 2020 Jun; 21(1):212. PubMed ID: 32493240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluctuations of haemoglobinaemia in chronic haemodialysis patients.
    De Meester J; Maes B; De Vriese A; De Moor B; Donck J; Helbert M; Bammens B; Jamar S
    Acta Clin Belg; 2011; 66(2):123-8. PubMed ID: 21630609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.